St. LouisBiotechnologyHealthcareHealth CareTherapeuticsHealth Diagnostics
Description
Geneoscopy, Inc. has appointed Matt Sargent as Chief Commercial Officer and Tyler Aldredge as Vice President of Operations to support the commercialization of ColoSense and expand the company's RNA platform to inflammatory bowel disease (IBD) diagnostics. Both appointees will play critical roles in bringing ColoSense to market and advancing precision diagnostics for IBD.
Company Information
Company
Geneoscopy
Location
2220 WELSCH INDUSTRIAL CT.
St. Louis, Missouri, United States
About
Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.
Fundz sees it the moment Geneoscopy changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
St. LouisBiotechnologyHealthcareHealth CareTherapeuticsHealth Diagnostics